

The landscape of male contraception

A narrative review

Karim Sidhom¹, Dhiraj S. Bal², Ryan Ramjiawan¹, Premal Patel^{1,3}

¹Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada; ²Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada; ³Men's Health Clinic Manitoba, Winnipeg, MB, Canada

Cite as: Sidhom K, Bal DS, Ramjiawan R, et al. The landscape of male contraception: A narrative review. *Can Urol Assoc J* 2024;18(10):353-9. <http://dx.doi.org/10.5489/cuaj.8728>

Published online June 10, 2024

ABSTRACT

Reproductive medicine has made significant advancements over the last 70 years, much of it in the way of female contraception. Reliable male contraception continues to be restricted to condoms and vasectomy. The purpose of this narrative review is to provide an overview of the contemporary usage of male contraceptive methods, including ethical and political standpoints, as well as to summarize current and future studies being done on male hormonal and non-hormonal contraceptive options.

INTRODUCTION

The ethical, medical, and legal considerations surrounding fertility and contraception within clinical practice have been a long-standing and sensitive debate. The landscape of human reproduction has undergone significant transformation due to advances in contraceptive methods and assisted reproductive technology.¹ The approved form of male contraception, apart from condom usage, is limited to vasectomy, as endorsed by the Canadian and American Urological Associations;² however, ongoing research into novel contraception holds promise for expanding the options available to men. This review explores the ethical principles, historical context, and current and future works on male contraception.

THE CURRENT LANDSCAPE OF CONTRACEPTION

Reliable family planning has been and continues to be an important part of modern North American culture. Over the past century, significant progress has been made to further elucidate effective contraception methods.³ Most of this research has focused on developing and improving female contraceptives via physical devices such as diaphragms, vaginal rings, implants, and intrauterine devices (IUDs), as well as oral birth control pills or injections.

Recently, more attention has been focused on male contraception. This would allow males to have more options for reliable contraception and, in theory, allow for a more active role in family planning. In fact, of the 21 commonly listed forms of contraception, only three involve active male participation: the male condom, withdrawal, and vasectomy.⁴ Historically, family planning has been under the purview of females, likely correlated to the relatively more efficacious female contraception options; however, this responsibility can be viewed as both an empowerment and a burden.⁵

In the current societal paradigm, the perception that women bear the role of contraception has also led them to bear the associated financial and health consequences.⁶ Though male hor-

monal contraception is not yet available, its acceptability has been polled in general public surveys worldwide, demonstrating that at least a quarter of men would consider hormonal contraception.⁷

ROE V. WADE

The medicalization of reproduction poses ethical dilemmas pertaining to women's health. Issues such as female sterilization, assisted reproduction, and interventions following contraception failure have always sparked complex discussions and debates, especially in recent years. These matters predominantly impact women, potentially resulting in their marginalization. In pursuit of fairness, a shared responsibility of contraception may provide a more equitable solution.

On June 24, 2022, the U.S. Supreme Court reversed the landmark decision of *Roe v. Wade*, a 1973 ruling that affirmed the constitutional right to abortion. This ruling marked the end of constitutionally protected abortion rights in the U.S., granting individual states the exclusive authority to regulate abortion. The Supreme Court draft, leaked on May 2, 2022, began with the sentence, "Abortion presents a profound moral issue on which Americans hold sharply opposing views," and set a clear direction for the case by asserting that "Roe was egregiously wrong from the start," and "We hold that *Roe* and *Casey* must be overruled." Against this legal backdrop, there has been a trend towards increased numbers of men seeking contraceptive methods, most notably vasectomy.⁸

KEY MESSAGES

- Reproductive medicine has changed significantly due to novel technologies and contraceptive strategies.
- Reliable and approved male contraception remains limited to condoms and vasectomies.
- The political landscape and ethics surrounding family planning strongly impacts contraceptive choice in men and the funding necessary to expand the options available.
- Much work has been done demonstrating the efficacy of hormonal contraceptive options in men, though these are not yet FDA-approved, and further work is underway to provide safe, reversible, and reliable male contraceptives.

Ghomeshi et al analyzed Google Trends data for the search volume of the keywords “vasectomy” and “tubal ligation” across the U.S., comparing data from two distinct time periods: April 25 to May 1, 2022, and May 2 to May 8, 2022. The term “vasectomy” saw a 121% increase in search volume, with a relative surge in the North and Southwestern states (most notably, Idaho), while “tubal ligation” saw a 70% increase.⁹

Datta et al further analyzed Google Trends search data between April 6 and July 5, 2022 for the following key terms: “tubal ligation, birth control pill, condom, IUD, vasectomy, morning after pill, and birth control shot.”¹⁰ Among these search terms, the keyword “vasectomy” showed the most significant surge in search interest, with a spike ratio of 7.14 times higher than the preceding baseline. Additionally, when quantified on the standardized scale of the Google Trends algorithm, with the highest indicator set at 100 and the lowest at 0, “vasectomy” exhibited a peak search interest value of 100 following the verdict.¹⁰

Tubal ligation also had a spike ratio of 5.89, with a search interest value of 53, while the terms “IUD,” “birth control pill,” and “condom,” collectively, had an average spike ratio of 1.7 (1.8, 1.75, and 1.57 respectively). Although limited, these search results provide insight into what American residents may have been thinking after the controversial decision. The results demonstrated a clear and growing interest in long-term

or permanent contraception. It is possible that this reaction arises from a sudden sense of loss of control over reproductive autonomy. Moving towards more definitive sterilization, whether for men or women, enables individuals to decisively regain that sense of empowerment.^{11,12}

Months later, Zhang et al further quantified this by comparing vasectomy rates before and after June 24, 2022 via a retrospective database study capturing over 87 million men aged 18–60 years across the U.S.¹³ They demonstrated a 20% increase in vasectomy volume when comparing the seven months prior and seven months following the *Roe v. Wade* court decision. More recent vasectomy prevalence rates for men aged between 15–49 range between 7.4–11.3% in Canada and the U.S.;¹⁴ however, these rates may increase in the coming years.

Although an active role for men would allow for a shared framework, the share would not be equal, as the ultimate result of contraceptive failure will always most affect the female partner given the nature of pregnancy. Hence, novel restrictive legislation around female contraception and abortion services has reverberations outside women’s health. Such aftereffects may propagate pressure in the realm of male reproductive research to develop alternatives to vasectomy.¹⁵

MALE CONTRACEPTION RESEARCH

The above limitations of male contraception methods could serve as the catalyst that both the medical and political spheres require to address the shortcomings in this space. Specifically, the idea of developing a dependable and widely accessible form of male hormonal contraception akin to “the pill” for women holds the potential to bridge this gap.¹⁶ Page et al discussed the main challenge of male hormonal contraception being the development of an accessible and efficacious market product that would be “the elusive male pill.”¹⁷ This underscores the challenges associated with the current state of male hormonal contraception development and use.¹⁸

This challenge is compounded not only by the stigma associated with testosterone as a pharmaceutical drug and the historical context through which its use has been and still is perceived, but also by the mode of administration. Testosterone is primarily administered via injections, further complicating its acceptance and accessibility. Oral administration is unfavorable due to first-pass metabolism and the associated liver toxicity. Such adverse effects have made the development of an oral pill challenging, and thus nasal, buccal, subdermal,

and transdermal routes have also been explored.¹⁹ Theoretically, if all options were available, the decision would come down to treatment burden and patient preference. Nevertheless, even with frequent injections of testosterone at regular intervals, infertility is not guaranteed.

Interference with spermatogenesis using exogenous androgens allows for the suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH); however, steroidal inhibition has not been proven, as some studies have shown incomplete suppression of the hypothalamic-pituitary-adrenal (HPA) axis.²⁰ A failure rate averaged from eight studies of male contraceptive efficacy demonstrates an effectivity of 97.7% and thus a Pearl Index value of 2.3, signifying the number of pregnancies that may happen for a method per 100 women over a year. By comparison, the Pearl Index rating for female oral contraceptives is 6.9% and for male condoms, 13%.^{17,21} It is crucial to mention that vasectomies also have early failure rates ranging from 0.3–9% within 3–6 months post-vasectomy, and late failure rates between 0.04–0.08%.²²

Past studies have demonstrated the efficacy of hormonal contraception using injectable regimes and non-injectable regimes. Three World Health Organization (WHO) studies demonstrated that weekly intramuscular injections of testosterone were able to provide highly effective, sustained, and reversible contraception within 120 days of treatment.^{23–25} To date, only eight hormonal male contraceptive efficacy studies have been conducted, showing a collective failure rate of 2.3%, defined as a sperm threshold of <1 million/ml with full reversibility.^{26,27}

Fertility does not have a specific threshold above which you are considered fertile, but rather seems to have a correlated spectrum of pregnancy success/expectancy. A normal sperm count is defined as >20 million/ml, and as per a study of 430 couples, within six months 65% of men with concentrations above 40 million/ml were successful, while 51.2% of men above 20 million/ml were successful.²⁷ Additionally, if below 20 million/ml, there was only a 36.4% chance of success. That said, most men will have recovery of the hypothalamic-pituitary-gonadal axis (HPGA) after testosterone use, with a varied timeline.²⁸

A 2006 study by Liu and Swerdloff stated that nearly all men will eventually demonstrate full reversibility from hormonal contraceptive regimens following a predictable time course within 24 months. Their dataset of 1549 previously eugonadal men aged 18–51 years showed that 67% of patients returned to a level

of 20 million/ml within six months, and 90% by 93 months. The speed of this recovery seemed to be directly related to patients of older age, Asian origin, shorter treatment duration, shorter-acting testosterone preparations, higher baseline sperm concentrations, faster onset of initial spermatogenic suppression, and lower baseline blood concentrations of luteinizing hormone.²⁹ Although most patients recover within half a year, some men may take multiple years to regain adequate sperm quality for reproduction depending on their specific interaction with testosterone replacement or supplementation.

Beyond efficacy, there seems to be more interest in a new method of male contraception. Multiple studies across the world have used surveys to validate interest in male hormonal contraception, finding that the majority of respondents would be willing to use such a method.^{30–33} Overall, at least 25% of men in any setting and in many countries, expressed their willingness to use “the pill” if it were available as an option;⁷ however, an additional question arose regarding whether, in such a scenario, women would trust men to reliably and effectively use this contraceptive pill.³⁴ Consequently, studies have also sought to determine the credibility of this cultural phenomenon, largely debunking its significance as Glasier et al found that only 2% of 1894 women attending family planning clinics across Scotland, China, and South Africa would not trust their partner to use the male equivalent of an oral pill.³²

FUTURE DIRECTIONS

Further studies are underway exploring transdermal, oral, and injectable hormonal contraception as well as non-hormonal vaso-occlusive, motility-based inhibition, and spermatogenesis-inhibitive mechanisms.^{35,36}

Hormonal contraception is based on the inhibition of spermatogenesis via exogenous stimulation of the HPGA—the negative feedback from which shuts down the HPGA. There are three contenders in the current male hormonal contraceptive space that are most promising for commercial use: Segesterone acetate + testosterone (nestorone/T), dimethandrolone undecanoate (DMAU), and 11 β -methyl-19-nortestosterone dodecylcarbonate (11 β -MNTDC).^{37,38}

Nestorone (segesterone acetate) is a synthetic progestosterone that suppresses the HPGA when used as an exogenous agonist. Nestorone/T is a gel formulation. Combined with testosterone, it allows the maintenance of serum testosterone via transdermal absorption in this capacity while shutting down intratesticular testosterone. There is currently an ongoing multicenter phase

2b randomized controlled trial (RCT) with 420 couples enrolled and designated to conclude in July 2024.¹⁷

DMAU acts as a prodrug to DMA, an agonist to both progesterone and androgen receptors. With a relative affinity of 18% to progesterone at the progesterone receptor and 400% to that of T at the androgen receptor, it effectively shuts down the HGPA while maintaining androgenic stimulation, thereby avoiding low testosterone symptoms. It is an injectable/oral compound. The intervention of oral testosterone compounds bypassing first metabolism represents a novelty in itself.

There is an ongoing phase I multicenter, double-blind RCT with an estimated 84 participants designated to conclude in December 2024 comparing intramuscular to subcutaneous injection pharmacodynamics.^{39,40} Another study looking at the use of oral DMAU with and without levonorgestrel at three different doses is currently recruiting, with a goal of enrolling 80 participants between two centers.

Thirdly, 11 β -MNTDC is an oral formulation that has already completed a phase 2b RCT between two centers in 2020, showing well-tolerated efficacy.^{41,42} One limitation of this study was the small sample size, including only 42 men; therefore, requiring further high-powered, concretizing work.⁴³ 11 β -MNTDC also works as a prodrug like DMAU converting to 11 β -MNT; however, with a significantly lower conversion rate (1/10th of DMAU to DMA).⁴⁴ 11 β -MNT is a modified testosterone that exhibits both progestin and androgen stimulation with oral daily dosing dependent upon administration with food.

Numerous non-hormonal methods have shown reversible efficacy while being minimally invasive. These include mechanisms that limit spermatogenesis and sperm motility, as well as vas deferens occlusion, to limit the passage of otherwise viable sperm. Spermatogenesis itself is a hormone-dependent process via Sertoli and Leydig cells downstream of LH and FSH stimulation; however, this process also necessitates further building blocks such as bromodomains, which work to facilitate protein-protein interactions needed for sperm morphology and motility, as well as testis-specific serine/threonine kinases (TSSK) needed for spermatogenesis.⁴⁵

Targeting bromodomain testis-specific protein/s (BRDT) and TSSK/s, reversible infertility has been shown in mice models, but has yet to be demonstrated in human trials.⁴⁶ One study evaluated this pathway in human subjects but used a non-testis-specific antagonist resulting in systemic toxicity from disulfiram-like reaction.⁴⁷

Selective inhibition of proteins that promote motility and capacitation are another target for male contraception.^{48,49} Eppin, soluble adenylyl cyclase, and specific spermatic ion channels are all proteins shown to be critical for this function. Many compounds have been studied and shown to inhibit these proteins in proof-of-concept animal studies; however, human trials have not yet been done.

Lastly, physical obstruction of the vas, effectively causing a synthetic, reversible obstructive azoospermia, has been an active area of research. This technique relies on the bilateral injection of a polymer into the vas that may be dissolved or cleared at a later date.⁵⁰⁻⁵² The leading contenders in this space include the three following compounds: reversible inhibition of sperm under guidance (RISUG), ADAM, and lastly, Valsalgel, otherwise known as "Plan A."

All of these are injectable, dissolvable hydrogel-like polymers that allow fluid to pass selectively but block sperm passage. They have been popularized in India, the U.S., and Australia. Each of these has undergone confirmatory animal trials demonstrating efficacy.⁵³ A human study as early as 1992 demonstrated the recovery of fertility in a group of 130 males post polyurethane gel removal. Zhao et al investigated a Chinese population where 260 polyurethane elastomer plugs were able to be surgically removed, resulting in all 130 participants' partners conceiving by four years post-removal.⁵³ Similarly, a 2022 study demonstrated efficacy of RISUG of vas occlusion and its reversibility in a group of 28 males.⁵⁴

A DOUBLE STANDARD?

To date, numerous studies have demonstrated nearly completely reversible suppression of spermatogenesis using intramuscular injection-based testosterone esters. A study by Behre et al precisely showed this with an intramuscular injection of 200 mg norethisterone enanthate combined with 1000 mg testosterone undecanoate administered every eight weeks; however, it was terminated early as per the recommendation of an external safety review committee established by the WHO based on adverse events documented in the study, which included reports of depression and mood changes, injection site pain, acne, and increased libido.⁵⁵

It is well known that testosterone supplementation causes increases in baseline hematocrit and may increase thromboembolic events. Additionally, its use is contraindicated in patients with metastatic prostate cancer, breast cancer, obstructive sleep apnea, and uncontrolled heart failure. Thus, testosterone is by no

means a benign drug and requires consistent monitoring to avoid suprathreshold toxicity.⁵⁶

Interestingly, of all formulations of testosterone replacement therapies (TRT), injectables tend to carry the most significant risk of increased hemoglobin and hematocrit;⁵⁷ however, if the goal is management of hypogonadal symptoms, TRT may achieve this at the cost or gain of infertility during treatment, but so too may human chorionic gonadotropin (hCG) and clomiphene citrate (CC); the difference being that hCG allows for the preservation of fertility while raising testosterone levels by stimulating the HGPA.⁵⁵

When compared to the initial Enovid study, the first oral pill developed in 1960 that received FDA approval, patients experienced significantly higher rates of objectively more severe adverse health effects.⁵⁸ Through a retrospective lens, it may be easy to judge the ethics surrounding its FDA approval, but it is important to note that the research milieu of the 1960s is considerably different than today's. That said, Suzanne W. Junod, FDA historian, released a statement in 1998 justifying these actions in the context of the political and medical climate of that time. The response seemingly seeks to address the "disillusionment... [and] varying interpretations of the wisdom of the Pill's original approval," she states.⁵⁹

Contemporary research and the healthcare landscape differ significantly from 60 years ago, making it challenging to claim a clear double standard in the development of male and female contraception. Additionally, the paucity of data regarding the imbalance in research funding between male and female fertility makes this question increasingly difficult to answer; however, one can argue that male contraception could and should have been developed simultaneously.

This raises questions about why it was not, revealing a complex historical narrative that goes beyond simple gender biases. The first study to examine the difference between male and female reproductive health funding, by Gumerova et al, described the value difference in both the U.K. and U.S. systems over a three-year period. Between January 2016 and December 2019, U.K. agencies awarded £11 767 190 to 18 projects for male-based research and £29 850 945 to 40 projects for female-based research.⁶⁰ Meanwhile, U.S. agencies funded 76 projects totalling \$59 257 746 for male-based research and 99 projects totalling \$83 272 898 for female-based research.

Nevertheless, proof of concept that testosterone-based injections have the ability to suppress spermatogenesis while being reversible was shown in 1939. There has been little further research in this regard,

as opposed to an abundance of female contraceptive research, suggesting a sex-based imbalance in priority and funding globally.

A MEDICAL ETHICS PERSPECTIVE

Medical ethics traditionally stands upon the following four pillars: respect for justice, beneficence, nonmaleficence, and autonomy, with a concern for scope of application.⁶¹

As it pertains to beneficence and nonmaleficence, physicians work for the benefit of their patients in balance with minimal harm. This ultimately leads one to analyze a benefit and risk ratio. Campelia et al recently discussed a novel shared risk analysis framework to address this ethical question.⁶² They argue a need for an equitable distribution of risks and benefits in contraception in the context of interdependent relationships; the benefit being objectively greater reproductive autonomy and participation in family planning. In so doing, the male may avoid unplanned parenthood and its obligations.

This autonomy is especially exemplified in both *Planned Parenthood v. Danforth* and *Planned Parenthood v. Casey*. The U.S. Supreme Court determined that laws requiring a spouse's consent for an abortion and equally that spousal notification of abortion were unconstitutional, respectively.⁶³ Considering these limits, an increase in vasectomy rates and interest in male contraception is understandable.

Ultimately, these methods give rise to reproductive autonomy and procreative liberty, allowing to better share the load of family planning. Historically, the autonomy gained by female contraceptive methods in women's rights movements was a stride of empowerment.⁶⁴ It was not until much later that the biopsychosocial and financial burdens of this power were recognized.⁶⁵

This perspective means that reproductive autonomy or procreative liberty comes at a cost. That said, if the first step is choice, the second would be accessibility.⁶⁶ Once or if available, male hormone contraception would then have to surmount barriers of access such as family planning provider education, public education and awareness, distance to care, and inadequate insurance and refilling regimens, among others.⁶⁷

The limits of access are critical to consider because although autonomy is basically a right to choose, the virtue of such autonomy is called into question when choices are limited. This restricted access to various contraceptive methods may create an illusion of reproductive choice.⁶⁸

Overall, as compared to the mid-1900s during the birth of female hormonal contraception, the landscape

surrounding contraception has drastically changed. Such a change primarily results from an evolved ethical approach via a shared risk framework. Currently, vasectomy and condoms provide methods for male contraception; however, these have pitfalls. The first has a relatively high fail rate and inconsistent use, while the latter is a surgical procedure in which reversibility can be challenging.^{69,70}

The architecture of choice among men's current contraception methods is thus limited. Therein lies the ethical responsibility to provide or at least pursue alternative options.

CONCLUSIONS

The above narrative reflects a review of past, present, and potential future male contraceptive methods with commentary on the politics that may surround these.⁷¹ With an almost 60-year gap in research, further study would help meet an unmet need and allow more options for family planning.⁶² Reproductive medicine is an evolving field, heavily influenced by basic science advancements, social stressors, and changes in political climate.

COMPETING INTERESTS: The authors do not report any competing personal or financial interests related to this work.

This paper has been peer reviewed.

REFERENCES

- Shreffler KM, Johnson DR, Scheuble LK. Ethical problems with infertility treatments: Attitudes and explanations. *Soc Sci J* 2010;47:731. <https://doi.org/10.1016/j.sosci.2010.07.012>
- Velez D, Pagani R, Mima M, Ohlander S. Vasectomy: A guidelines-based approach to male surgical contraception. *Fertil Steril* 2021;115:1365-8. <https://doi.org/10.1016/j.fertnstert.2021.03.045>
- Service CA, Puri D, Hsieh TC, Patel DP. Emerging concepts in male contraception: A narrative review of novel, hormonal and non-hormonal options. *Ther Adv Reprod Health* 2023;17. :2633494122113833 <https://doi.org/10.1177/26334941221138333>
- Bansode OM, Sarao MS, Cooper DB. Contraception. *StatPearls*. Published online July 25, 2022.
- National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Committee on Population. Sferazza C. *Family Planning, Women's Empowerment, and Population and Societal Impacts*. 2021. <https://doi.org/10.17226/26023>
- Campo-Engelstein L. Contraceptive justice: Why we need a male pill. *Virtual Mentor* 2012;14:146-51. <https://doi.org/10.1001/VIRTUALMENTOR.2012.14.2.MSOC1-1202>
- Glazier A. Acceptability of contraception for men: A review. *Contraception* 2010;82:453-6. <https://doi.org/10.1016/j.contraception.2010.03.016>
- Bole R, Lundy SD, Pei E, et al. Rising vasectomy volume following reversal of federal protections for abortion rights in the United States. *Int J Impot Res* 2023;1-4. <https://doi.org/10.1038/s41443-023-00672-x>
- Ghomeshi A, Diaz P, Henry V, et al. The interest in permanent contraception peaked following the leaked supreme court majority opinion of Roe vs. Wade: A cross-sectional Google Trends analysis. *Cureus* 2022;14:e30582. <https://doi.org/10.7759/CUREUS.30582>
- Datta PK, Chowdhury SR, Aravindan A, et al. Looking for a silver lining to the dark cloud: A Google Trends Analysis of contraceptive interest in the United States post Roe vs. Wade verdict. *Cureus* 2022;14:e27012. <https://doi.org/10.7759/CUREUS.27012>
- Chalmers J, Petterson A, Woodford L, et al. The rights of man: Libertarian concern for men's, but not women's, reproductive autonomy. *Polit Psychol* 2023;44:603-25. <https://doi.org/10.1111/POPS.12867>
- Purdy L. Women's reproductive autonomy: Medicalisation and beyond. *J Med Ethics* 2006;32:287. <https://doi.org/10.1136/JME.2004.013193>
- Zhang TR, Able C, Ramasamy R, Kohn TP. United States vasectomy incidence rises after the reversal of Roe v. Wade in a national clinical and claims database. *Fertil Steril* 2023;120:196-7. <https://doi.org/10.1016/j.fertnstert.2023.03.025>
- Jacobstein R, Radloff S, Khan F, et al. *Down But Not Out: Vasectomy Is Faring Poorly Almost Everywhere-We Can Do Better To Make It A True Method Option*. www.ghspjournal.org
- Sax MR. Seeking vasectomy in post-Dobbs America: The male counterpart response to the reversal of Roe v Wade as evidenced by Google search trends. *Fertil Steril* 2022;118:1189. <https://doi.org/10.1016/j.fertnstert.2022.10.006>
- Amory JK. Male hormonal contraceptives. *Minerva Ginecol* 2006;58:215-26. <https://doi.org/10.2165/00024677-200504060-00002>
- Page ST, Blithe D, Wang C. Hormonal male contraception: Getting to market. *Front Endocrinol (Lausanne)* 2022;13. <https://doi.org/10.3389/FENDO.2022.891589>
- Amory JK, Page ST, Bremner WJ. Drug insight: Recent advances in male hormonal contraception. *Nat Clin Pract Endocrinol Metab* 2006;2:32-41. <https://doi.org/10.1038/NCPENDEMET0069>
- Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. *Transl Androl Urol* 2016;5:834. <https://doi.org/10.21037/TAU.2016.07.10>
- Wallace EM, Gow SM, Wu FCW. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations. *J Clin Endocrinol Metab*. 1993;77:290-293. <https://doi.org/10.1210/JCEM.77.1.8325955>
- Berglund Scherwitzl E, Lundberg O, Kopp Kallner H, et al. Perfect-use and typical-use Pearl Index of a contraceptive mobile app. *Contraception* 2017;96:420. <https://doi.org/10.1016/j.CONTRACEPTION.2017.08.014>
- Zini A, Grantmyre J, Chan P. CUA guideline: Vasectomy. *Can Urol Assoc J* 2016;10:E274. <https://doi.org/10.5489/CUAJ.4017>
- Contraceptive efficacy of testosterone-induced azoospermia in normal men. *Lancet*. 1990;336:955-9. [https://doi.org/10.1016/0140-6736\(90\)92416-F](https://doi.org/10.1016/0140-6736(90)92416-F)
- Griffin PD, Aribarg A, Gui-yuan Z, et al. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. *Fertil Steril*. 1996;65:821-9. [https://doi.org/10.1016/S0015-0282\(16\)58221-1](https://doi.org/10.1016/S0015-0282(16)58221-1)
- Gu Y, Liang X, Wu W, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. *J Clin Endocrinol Metab* 2009;94:1910-5. <https://doi.org/10.1210/JC.2008-1846>
- Bonde JPE, Ernst E, Jensen TK, et al. Relation between semen quality and fertility: A population-based study of 430 first-pregnancy planners. *Lancet* 1998;352:1172-7. [https://doi.org/10.1016/S0140-6736\(97\)10514-1](https://doi.org/10.1016/S0140-6736(97)10514-1)
- Sharpe RM. Sperm counts and fertility in men: A rocky road ahead. *Science & Society Series on Sex and Science. EMBO Rep* 2012;13:398-403. <https://doi.org/10.1038/EMBOR.2012.50>
- Liu PY, Swerdloff RS, Christenson PD, et al. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: An integrated analysis. *Lancet* 2006;367:1412-1420. [https://doi.org/10.1016/S0140-6736\(06\)68614-5](https://doi.org/10.1016/S0140-6736(06)68614-5)
- Esposito M, Salerno M, Calvano G, et al. Impact of anabolic androgenic steroids on male sexual and reproductive function: A systematic review. *Panminerva Med* 2023;65:43-50. <https://doi.org/10.23736/S0031-0808.22.04677-8>
- Heinemann K, Saad F, Wiesemes M, et al. Attitudes toward male fertility control: Results of a multinational survey on four continents. *Hum Reprod* 2005;20:549-56. <https://doi.org/10.1093/HUMREP/DEH574>
- Weston GC, Schlipalius ML, Bhuiinnein MN, et al. Will Australian men use male hormonal contraception? A survey of a postpartum population. *Med J Aust* 2002;176:208-10. <https://doi.org/10.5694/11326-5377.2002.TB04374.X>
- Glazier R, Anakwe D, Everington CW, et al. Would women trust their partners to use a male pill? *Hum Reprod* 2000;15:646-9. <https://doi.org/10.1093/HUMREP/15.3.646>
- Martin CW, Anderson RA, Cheng L, et al. Potential impact of hormonal male contraception: Cross-cultural implications for development of novel preparations. *Hum Reprod* 2000;15:637-45. <https://doi.org/10.1093/HUMREP/15.3.637>
- Eberhardt J, Van Wersch A, Meikle N. Attitudes towards the male contraceptive pill in men and women in casual and stable sexual relationships. *BMJ Sex Reprod Health* 2009;35:161-5. <https://doi.org/10.1136/bmjsex.2008.000000>
- Page ST, Blithe D, Wang C. Hormonal Male Contraception: Getting to Market. *Front Endocrinol (Lausanne)* 2022;13:891589. <https://doi.org/10.3389/fendo.2022.891589>

36. Louwagie EJ, Quinn GFL, Pond KL, et al. Male contraception: narrative review of ongoing research. *Basic Clin Androl* 2023;33:30. <https://doi.org/10.1186/s12610-023-00204-z>
37. Amory JK, Blithe DL, Sitruk-Ware R, et al. Design of an international male contraceptive efficacy trial using a self-administered daily transdermal gel containing testosterone and segestosterone acetate (Nestorone). *Contraception* 2023;124. <https://doi.org/10.1016/j.contraception.2023.110064>
38. Study Details | Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception | ClinicalTrials.gov. Accessed March 8, 2024. <https://clinicaltrials.gov/study/NCT03452111>
39. Study Details | Study of spermatogenesis suppression with DMAU alone or with LNG versus placebo alone in normal men | ClinicalTrials.gov. Accessed March 8, 2024. <https://clinicaltrials.gov/study/NCT03455075>
40. Study Details | Injectable DMAU for male contraception in healthy male volunteers (CCN015) | ClinicalTrials.gov. Accessed March 8, 2024. <https://clinicaltrials.gov/study/NCT02927210>
41. Yuen F, Thirumalai A, Fernando FA, et al. Comparison of metabolic effects of the progestational androgens dimethandrolone undecanoate and 11β-MNTDC in healthy men. *Andrology* 2021;9:1526-39. <https://doi.org/10.1111/ANDR.13025>
42. Yuen F, Thirumalai A, Pham C, et al. Daily oral administration of the novel androgen 11β-MNTDC markedly suppresses Serum Gonadotropins in healthy men. *J Clin Endocrinol Metab* 2020;105. <https://doi.org/10.1210/CLINEM/DGAA032>
43. Wu S, Yuen F, Swerdloff RS, et al. Safety and pharmacokinetics of single-dose novel oral androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in men. *J Clin Endocrinol Metab* 2019;104:629-638. <https://doi.org/10.1210/IC.2018-01528>
44. Yuen F, Thirumalai A, Pham C, et al. Daily oral administration of the novel androgen 11β-MNTDC markedly suppresses Serum Gonadotropins in healthy men. *J Clin Endocrinol Metab* 2020;105. <https://doi.org/10.1210/CLINEM/DGAA032>
45. Salicioni AM, Gervasi MG, Sosnik J, et al. Testis-specific serine kinase protein family in male fertility and as targets for non-hormonal male contraception. In: *Biology of Reproduction*. Vol 103. Oxford University Press; 2020:264-74. <https://doi.org/10.1093/biolre/i0aa064>
46. Heller CG, Moore DJ, Paulsen CA. Suppression of spermatogenesis and chronic toxicity in men by a new series of bis(dichloroacetyl) diamines. *Toxicol Appl Pharmacol*. 1961;3:1-11. [https://doi.org/10.1016/0041-008X\(61\)90002-3](https://doi.org/10.1016/0041-008X(61)90002-3)
47. Dcunha R, Hussein RS, Ananda H, et al. Current insights and latest updates in sperm motility and associated applications in assisted reproduction. *Reprod Sci* 2022;29:7-25. <https://doi.org/10.1007/S43032-020-00408-Y>
48. Balbach M, Ghanem L, Rossetti T, et al. Soluble adenyllyl cyclase inhibition prevents human sperm functions essential for fertilization. *Mol Hum Reprod* 2021;27. <https://doi.org/10.1093/molehr/gaab054>
49. Rahban R, Nef S. CatSper: The complex main gate of calcium entry in mammalian spermatozoa. *Mol Cell Endocrinol* 2020;518:110951. <https://doi.org/10.1016/j.mce.2020.110951>
50. Study Details | Safety Evaluation of the ADAM System | ClinicalTrials.gov. Accessed March 8, 2024. <https://www.clinicaltrials.gov/study/NCT05134428>
51. Waller D, Bolick D, Lissner E, Premanandan C, Gamberman G. Reversibility of Vasalgel™ male contraceptive in a rabbit model. *Basic Clin Androl* 2017;27. <https://doi.org/10.1186/S12610-017-0051-1>
52. Guha SK, Singh G, Ansari S, et al. Phase II clinical trial of a vas deferens injectable contraceptive for the male. *Contraception*. 1997;56:245-50. [https://doi.org/10.1016/S0010-7824\(97\)00142-x](https://doi.org/10.1016/S0010-7824(97)00142-x)
53. Sheng-Cai Z, Yi-He L, Rui-Chuan Y, et al. Recovery of fertility after removal of polyurethane plugs from the human vas deferens occluded for up to 5 years. *Int J Androl*. 1992;15:465-7. <https://doi.org/10.1111/J.1365-2605.1992.TB01139.X>
54. Lohiya NK, Ansari AS, Sadasukhi TC, et al. RISUG® offers early contraception: An experience during Phase III clinical trials. *J Reprod Health Med* 2022;3:11. https://doi.org/10.25259/JRHM_8_2022
55. Behre HM, Zitzmann M, Anderson RA, et al. Efficacy and safety of an injectable combination hormonal contraceptive for men. *J Clin Endocrinol Metab* 2016;101:4779-88. https://doi.org/10.1210/JC.2016-2141/SUPPL_FILE/JC-16-2141.PDF
56. Jones SD, Dukovac T, Sangkum P, et al. Erythrocytosis and polycythemia secondary to testosterone replacement therapy in the aging male. *Sex Med Rev* 2015;3:101-12. <https://doi.org/10.1002/SMRJ.43>
57. Androgen Replacement - PubMed. Accessed March 8, 2024. <https://pubmed.ncbi.nlm.nih.gov/30521274/>
58. History of Oral Contraception. *AMA J Ethics* 2000;2(6). <https://doi.org/10.1001/VIRTUALMENTOR.2000.2.6.DYKN1-0006>
59. Burrows, Vanessa. FDA's Approval of the First Oral Contraceptive, Enovid.
60. Gumerova E, De Jonge CJ, Barratt CLR. Research funding for male reproductive health and infertility in the UK and USA [2016–2019]. *Hum Fertil* 2023;26:439-49. <https://doi.org/10.1080/14647273.2022.2045521>
61. Gillon R. Medical ethics: Four principles plus attention to scope. *BMJ* 1994;309:184. <https://doi.org/10.1136/BMJ.309.6948.184>
62. Campella GD, Abbe C, Nickels LM, et al. "Shared risk": Reframing risk analysis in the ethics of novel male contraceptives. *Contraception* 2020;102:67. <https://doi.org/10.1016/J.CONTRACEPTION.2020.05.014>
63. Hales SD. Abortion and fathers' rights. 1996:5-26. https://doi.org/10.1007/978-1-59259-450-4_1
64. Johnston J, Zacharias RL. The future of reproductive autonomy. *Hastings Cent Rep* 2017;47:56. <https://doi.org/10.1002/HAST.789>
65. Torres A, Forrest JD. The costs of contraception. *Fam Plann Perspect*. 1983;15:70-2.
66. Bajos N, Leridon H, Goulard H, et al. Contraception: From accessibility to efficiency. *Hum Reprod* 2003;18:994-9. <https://doi.org/10.1093/HUMREP/DEG215>
67. Ali AM, Cobran EK, Young HN. Barriers associated with access to prescription medications in patients diagnosed with Type 2 Diabetes Mellitus treated at federally qualified health centers. *Pharmacy* 2022;10:79. <https://doi.org/10.3390/PHARMACY10040079>
68. Zeiler K. Reproductive autonomous choice—a cherished illusion? Reproductive autonomy examined in the context of preimplantation genetic diagnosis. *Med Health Care Philos* 2004;7:175-83. <https://doi.org/10.1023/B:MHEP.0000034323.68025.D5>
69. Fonner VA, Kennedy CE, O'Reilly KR, et al. Systematic assessment of condom use measurement in evaluation of HIV prevention interventions: need for standardization of measures. *AIDS Behav* 2014;18:2374. <https://doi.org/10.1007/S10461-013-0655-1>
70. Patel AP, Smith RP. Vasectomy reversal: A clinical update. *Asian J Androl* 2016;18:365. <https://doi.org/10.4103/1008-682X.175091>
71. Savulescu PJ, Wilkinson PD. Consequentialism and the Law in Medicine. *Philosophical Foundations of Medical Law* 2019:68-87. <https://doi.org/10.1093/oso/9780198796558.003.0005>

CORRESPONDENCE: Dr. Karim Sidhom, Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada; sidhomk@myumanitoba.ca

Visit <https://www.cua.org/UROpedia> to complete the questionnaire associated with this article. This program is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of RCPC, and approved by the CUA. You may claim a maximum of 1 hour of credit.